Pendal Group Ltd boosted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 27.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,240 shares of the company's stock after acquiring an additional 693 shares during the quarter. Pendal Group Ltd's holdings in Johnson & Johnson were worth $572,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Veracity Capital LLC grew its stake in shares of Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company's stock worth $888,000 after acquiring an additional 59 shares during the period. Sandy Cove Advisors LLC boosted its holdings in Johnson & Johnson by 1.6% in the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company's stock worth $605,000 after purchasing an additional 60 shares during the last quarter. Paces Ferry Wealth Advisors LLC grew its position in Johnson & Johnson by 0.7% in the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company's stock worth $1,425,000 after purchasing an additional 62 shares during the period. Mason & Associates Inc raised its stake in Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company's stock valued at $215,000 after buying an additional 62 shares during the last quarter. Finally, Magnolia Capital Advisors LLC lifted its holdings in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company's stock valued at $1,451,000 after buying an additional 62 shares during the period. 67.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. Atlantic Securities upped their price objective on Johnson & Johnson from $160.00 to $168.00 and gave the company a "neutral" rating in a research report on Wednesday, January 25th. Piper Sandler reduced their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. UBS Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday. They issued a "neutral" rating and a $164.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Finally, Guggenheim started coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They set a "neutral" rating and a $161.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $173.67.

Johnson & Johnson Stock Up 1.0 %

JNJ opened at $153.31 on Thursday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The stock has a market cap of $399.26 billion, a price-to-earnings ratio of 22.75, a price-to-earnings-growth ratio of 2.63 and a beta of 0.54. The firm's fifty day moving average is $158.62 and its 200 day moving average is $167.29.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts' consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business's quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.13 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.95%. The ex-dividend date was Friday, February 17th. Johnson & Johnson's payout ratio is currently 67.06%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.35% of the company's stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.

Read More

• Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
• Dave & Buster's Rebound Could Score for Investors
• Cal-Maine: Is it Time to Chase this Stock Higher?
• The Most Important Warren Buffett Stock for Investors: His Own
• Three Mid Caps Wall Street Sees Doubling Within 12 Months
• It's No Stretch: Lululemon Could Break Out of its Range

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.